Sanofi (BKK:SANOFI80)
Thailand · Delayed Price · Currency is THB | Market Cap | 3.65T -25.1% |
| Revenue (ttm) | 1.73T +5.5% |
| Net Income | 289.30B +40.5% |
| EPS | 236.05 +43.6% |
| Shares Out | n/a |
| PE Ratio | 12.60 |
| Forward PE | 9.53 |
| Dividend | 0.10 (3.52%) |
| Ex-Dividend Date | May 13, 2025 |
| Volume | 25,619 |
| Average Volume | 272,226 |
| Open | 2.940 |
| Previous Close | 2.920 |
| Day's Range | 2.920 - 2.980 |
| 52-Week Range | 2.780 - 3.880 |
| Beta | n/a |
| RSI | 59.35 |
| Earnings Date | Apr 23, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for onc... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial numbers in EUR Financial StatementsNews
Sanofi (SNY) Gains Japanese Approval for Dupixent in Treating Bullous Pemphigoid
Sanofi (SNY) Gains Japanese Approval for Dupixent in Treating Bullous Pemphigoid
Sanofi And Regeneron's Dupixent Approved In Japan For Bullous Pemphigoid
(RTTNews) - Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) announced that Japan's Ministry of Health, Labour and Welfare has approved Dupixent (dupilumab) for adults with moderate-to-severe bullous...
Press release: Availability of the Q1 2026 aide-mémoire
Availability of the Q1 2026 aide-mémoire Paris, France – March 24, 2026. Sanofi announced today the availability of its Q1 2026 aide-mémoire on the "Investors" page of the company's website: First qua...
Press Release: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Press Release: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe patients was based on pivotal study results show...
Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment
Kali Therapeutics said on Monday it has entered into a licensing agreement with French drugmaker Sanofi to develop the privately held firm's experimental treatment for several autoimmune diseases.
Sanofi launches innovation and operation centre in China
French drugmaker Sanofi launched an innovation and operation centre in the southwestern Chinese city of Chengdu on Thursday, the company said in a statement released on its Chinese social med...
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Sanofi's Venglustat Gets FDA Breakthrough Therapy Designation For Type 3 Gaucher Disease
(RTTNews) - Sanofi (SNY, SAN.PA, SNYNF) announced that the US Food and Drug Administration has granted Breakthrough Therapy designation to Venglustat for the treatment of neurological manifestations o...
Mirecule Expands Strategic FSHD Collaboration with Sanofi
GAITHERSBURG, Md.--(BUSINESS WIRE)--Mirecule expands strategic collaboration with Sanofi on advancement of best-in-class ARC treatment of Facioscapulohumeral Muscular Dystrophy (FSHD).
Press Release: Sanofi's venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
Sanofi's venglusta t earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026 . The US Food and Drug Administration (FDA) has granted Breakthrough Therapy des...
Press Release: Sanofi's venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
Sanofi's venglusta t earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026 . The US Food and Drug Administration (FDA) has granted Breakthrough Therapy desi...
Big drugmakers must face US overcharge claims on medications for low-income patients
A U.S. appeals court on Tuesday revived a whistleblower lawsuit accusing four large drugmakers of defrauding the federal and state governments out of hundreds of millions of dollars by overcharging ...
The Big 3: PR, ELF, SNY
From oil, beauty, and therapeutic resource stocks, @ElliottWaveTrader's Tammy Marshall turns to three companies she sees as unsung market opportunities. The Fibonacci Princess offers insight and exa...
Sanofi: An Undervalued Stock For Long-Term Dividend Growth Investors
Sanofi has increased its dividend for 31 consecutive years. That's a fantastic track record. Sanofi increased its revenue from €34.7 billion in FY 2016 to €43.6 billion in FY 2025. That's a compound a...
Sanofi: Information concerning the total number of voting rights and shares - February 2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g...
Brazil drugmaker EMS eyes overseas deals after buying Sanofi unit
Brazilian drugmaker EMS is open to fresh acquisitions to expand internationally after inking a major deal to buy Sanofi's Brazil-based generic drugmaker Medley, and is gearing up to launch its own se...
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures
Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026 Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026 Lorigerlimab Phase 2 LINNET study update in mid-2026 IND submission for MGC030,...
P/E Ratio Insights for Sanofi
In the current session, Sanofi Inc. (NASDAQ: SNY) is trading at $43.87, after a 1.54% decrease. Over the past month, the stock fell by 9.80% , and in the past year, by 25.32% . With performance like ...
Sanofi (SNY) to Sell Medley to EMS in $500M+ Deal
Sanofi (SNY) to Sell Medley to EMS in $500M+ Deal
EMA Panel Backs Moderna's COVID-Flu Shot, Sanofi's Sleeping Sickness Drug, Ipsen's Cancer Drug
(RTTNews) - At its February 2026 meeting, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted positive opinions for Moderna's combined COVID-19 -Influenza vacci...
Need Growing EPS And Dividends? Prescribe Sanofi
Sanofi is deeply undervalued, trading at a 29% discount to a $65 fair value estimate, with a forward P/E of 9.2 versus a 10-year average of 13. Robust growth is driven by blockbuster drugs like Dupixe...
Press Release: Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director
Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director
Press Release: Filing of an amendment to the French "Document d'Enregistrement Universel" containing the Annual Financial Report
Filing of an amendment to the French "Document d'Enregistrement Universel" containing the Annual Financial Report Paris, March 4, 2026 . Sanofi announces today the filing of an amendment to its "Docum...
Press Release: Filing of an amendment to the French “Document d'Enregistrement Universel” containing the Annual Financial Report
Filing of an amendment to the French “Document d'Enregistrement Universel” containing the Annual Financial Report Paris, March 4, 2026. Sanofi announces today the filing of an amendment to its “Docume...